Investment Thesis
Vaxart demonstrates exceptional revenue growth (726.7% YoY) and reported profitability, but faces a critical red flag: operating cash flow of $7.7M represents only 47% of reported net income ($16.3M), suggesting significant earnings quality concerns or unsustainable revenue recognition. The biotech company maintains a healthy balance sheet with 0.20x debt/equity and $53.8M cash, but the massive disconnect between reported earnings and actual cash generation requires urgent clarification before any bullish stance is justified.
Strengths
- Exceptional revenue growth of 726.7% YoY with positive net income ($16.3M) and operating income ($18.1M)
- Conservative capital structure with 0.20x debt/equity ratio and strong $53.8M cash position (29% of assets)
- Solid liquidity metrics (1.57x current ratio) and reasonable returns (18.6% ROE, 8.8% ROA)
Risks
- Critical earnings quality concern: operating cash flow ($7.7M) is only 47% of net income ($16.3M), indicating potential accounting issues or aggressive revenue recognition
- Extremely thin free cash flow margin (3.2%) despite 7.6% operating margin suggests minimal actual cash generation from massive revenue base
- Missing gross margin data prevents verification of core product profitability; biotech sector regulatory and R&D execution risks
Key Metrics to Watch
- Operating cash flow trend and cash conversion rate relative to net income
- Revenue composition and sustainability (government contracts vs. commercial sales)
- Accounts receivable and working capital changes driving OCF/earnings disconnect
Financial Metrics
Revenue
237.3M
Net Income
16.3M
EPS (Diluted)
$0.07
Free Cash Flow
7.6M
Total Assets
186.1M
Cash
53.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
7.6%
Net Margin
6.9%
ROE
18.6%
ROA
8.8%
FCF Margin
3.2%
Balance Sheet & Liquidity
Current Ratio
1.57x
Quick Ratio
1.57x
Debt/Equity
0.20x
Debt/Assets
52.8%
Interest Coverage
N/A
Long-term Debt
17.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T23:18:24.886196 |
Data as of: 2025-12-31 |
Powered by Claude AI